<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63714">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845337</url>
  </required_header>
  <id_info>
    <org_study_id>2012-005282-12</org_study_id>
    <nct_id>NCT01845337</nct_id>
  </id_info>
  <brief_title>Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine</brief_title>
  <acronym>TOFFEE</acronym>
  <official_title>Toxicity OF Fluoropyrimidines: A Comparative Study of the Cardiotoxicity of capEcitabine and tEysuno</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Capecitabine is a chemotherapy drug used to treat many types of cancer including bowel and
      stomach cancer. Unfortunately a side effect of this drug is that it causes heart problems
      including heart attacks. An alternative drug, called teysuno is used extensively in other
      countries instead of capecitabine and appears to have less of a bad effect on the heart
      whilst still killing cancer cells. This study will investigate the effect of these two drugs
      on the heart and blood vessels and will be the first of its kind in humans.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary endpoint of the study will be a difference in the duration of ST deviation pre-treatment and during treatment.</measure>
    <time_frame>Pre treatment and between day 5-7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This will be recorded using Del Mar Reynolds Lifecard CF/Lifecard 12 recorders, which will record 12 leads over 24 hours and continuously if the storage card is changed daily. Pre-treatment control ECGs will be recorded for 24 hours. Continuous 12-lead monitoring shall be recorded for three days between day 5 and 7 of treatment.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine single agent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine /Oxaliplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 1000 mg/m2 twice daily, days 1-14 every 21 days (in frail or elderly patients, a CAP dose of 750 mg/m2 BD should be considered). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teysuno single agent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Teysuno will be administered at a dose of 30 mg/m2 twice daily, for 14 days, with a subsequent 7-day rest period. Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily:  40mg (BSA &lt; 1.5 m2),  45 mg (BSA  1. 5 to &lt; 1.7 m2),  55mg (BSA 1.7 - 1.9 m2),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teysuno/ Oxaliplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Teysuno will be administered orally at a dose of  25mg/m2 twice daily, days 1-14 every 21 days Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily:  35mg (BSA &lt; 1.5 m2),  40mg (BSA  1.5 to &lt; 1.7 m2),  45mg (BSA 1.7 - 1.9 m2),  50mg (BSA &gt;1.9 m2).  Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teysuno</intervention_name>
    <arm_group_label>Teysuno single agent</arm_group_label>
    <arm_group_label>Teysuno/ Oxaliplatin</arm_group_label>
    <other_name>Tegafur / Gimeracil / Oteracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Capecitabine single agent</arm_group_label>
    <arm_group_label>Capecitabine /Oxaliplatin</arm_group_label>
    <other_name>Xeloda tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients at least 18 years or over with no upper age limit.

          -  Confirmed advanced or metastatic oesophageal, gastric, gastro-oesophageal, small
             bowel, colorectal, hepatobiliary or pancreatic cancer.

          -  Suitable for treatment with fluoropyrimidine, either alone or in combination with
             oxaliplatin.

          -  WHO performance status (PS) 0, 1 or 2  and considered by responsible consultant to be
             fit to undergo planned chemotherapy and cardiac investigations.

          -  Baseline laboratory tests (within 1 week prior to starting treatment):

               -  Neutrophils &gt;1.5 x109 /L and platelet count &gt; 100 x109 /L

               -  Serum bilirubin &lt;3 x upper limit of normal (ULN), alkaline phosphatase &lt;5x ULN,
                  and serum transaminase (either AST or ALT) &lt;5 x ULN

               -  Estimated creatinine clearance &gt;50 mL/min (Cockcroft and Gault, adjusted for
                  BSA; Appendix ?) or estimated glomerular filtration rate (eGFR) &gt;50 mL/min.
                  [Patients with Cr Cl 30-50 mL/min will be included but should be treated at a
                  reduced dose (see master prescription chart)]

          -  For women of childbearing potential; negative pregnancy test and adequate
             contraceptive precautions.

          -  Effective contraception for male patients if the risk of conception exists.

          -  Written informed consent for participation in the trial.

        Exclusion Criteria:

          -  Patients who are unfit for the chemotherapy regimens in this protocol, such as:

               -  Known intolerance to CAP or other FPs

               -  Severe uncontrolled concurrent medical illness likely to interfere with protocol
                  treatments

               -  Poorly controlled angina or MI  in previous 6 months

               -  Any psychiatric or neurological condition which is felt likely to compromise the
                  patient's ability to give informed consent or to comply with oral medication

               -  Partial or complete bowel obstruction

               -  Pre-existing neuropathy &gt; grade 1 if combination therapy proposed

          -  Patients on therapeutic anticoagulation (warfarin or LMWH).

          -  Patients unable to lie flat.

          -  Patients unable to withstand the visits and cardiovascular investigations proposed
             within the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sally Clive, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally Clive, MBChB MD</last_name>
    <phone>0131 777 350</phone>
    <email>sallyclive@nhslothian.scot.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalie J Peel, MBChB</last_name>
    <phone>07751577040</phone>
    <email>nataliepeel@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sally Clive, MBChB</last_name>
      <phone>0131 777 350</phone>
    </contact>
    <investigator>
      <last_name>Sally Clive, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalie Peel, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>May 1, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
